Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
At Affimed, we are committed to improving outcomes for patients with cancer. Our s...
At Affimed, we are committed to improving outco...
We are a leading, rapidly growing synthetic biology company that has developed a d...
We are a leading, rapidly growing synthetic bio...
We help save lives by improving verbal and written communications that occur betwe...
We help save lives by improving verbal and writ...
Corcept is a pharmaceutical company engaged in the discovery, development and comm...
Corcept is a pharmaceutical company engaged in ...
We are a clinical-stage specialty pharmaceutical company dedicated to the developm...
We are a clinical-stage specialty pharmaceutica...
Mylan is a global pharmaceutical company committed to setting new standards in hea...
Mylan is a global pharmaceutical company commit...
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...
MacroGenics is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.